2025
Association between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis
Theprungsirikul P, Wang R, Ahmad I, Neparidze N, Ma X, Chang S, Wang S. Association between patient demographics and smoldering multiple myeloma progression to multiple myeloma: A SEER-Medicare data analysis. Clinical Lymphoma Myeloma & Leukemia 2025 DOI: 10.1016/j.clml.2025.06.016.Peer-Reviewed Original ResearchSmoldering multiple myelomaSmoldering multiple myeloma patientsMultiple myelomaPatient demographicsProgression to multiple myelomaSymptomatic multiple myelomaDevelopment of hypercalcemiaCox proportional hazards modelsRisk stratification modelConfidence intervalsNon-cancer controlsEstimate hazard ratiosProportional hazards modelNon-cancer patientsSymptomatic MMRandom sample of Medicare beneficiariesSMM patientsRenal failureAnalyzed SurveillanceSEER-MedicareNatural history modelHazard ratioBone diseasePatientsSample of Medicare beneficiariesHigh-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma.
Fiala M, Ji M, Slade M, Huber J, Shih Y, Wang M, Colditz G, Wang S, Vij R, Chang S. High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma. JCO Oncology Practice 2025, op2400978. PMID: 40354593, DOI: 10.1200/op-24-00978.Peer-Reviewed Original ResearchStem-cell transplantationMultiple myelomaTreatment initiationHigh-deductible health plan enrollmentHigh-deductible health plansTransplant receiptShorter time to treatment initiationTime to treatment initiationOOP costsHealth Insurance DatabaseAssociated with delayStatistically significant differenceHealth plansPlan enrolleesOut-of-pocket health care costsYounger patientsOut-of-pocket (OOP) costsCox regressionPrimary outcomeMultivariate analysisSecondary outcomesInsurance DatabasePatientsTotal health careHealth care costs
2024
Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review
Li Y, Hsu S, Wang R, Theprungsirikul P, Neparidze N, Chang S, Wang S. Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e222-e231. PMID: 39730300, PMCID: PMC11911095, DOI: 10.1016/j.clml.2024.12.006.Peer-Reviewed Original ResearchProgression to MMMultiple myelomaNewcastle-Ottawa ScaleMonoclonal gammopathyRisk of progression to MMIncreased riskProgression to multiple myelomaRisk estimatesHigher body mass indexPre-malignant conditionBody mass indexRandom-effects modelMass indexCohort studyPatient characteristicsFemale sexMale genderMethodological qualityNewcastle-OttawaBlack raceRisk ratioMGUSRisk factorsPublication biasSystematic reviewAsymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study.
Ji M, Shih Y, Huber J, Wang M, Feuer E, Etzioni R, Wang S, Chang S. Asymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study. Cancer Epidemiology Biomarkers & Prevention 2024, 33: 1690-1697. PMID: 39106151, PMCID: PMC11611677, DOI: 10.1158/1055-9965.epi-24-0490.Peer-Reviewed Original ResearchNHB populationNHW populationsPreclinical durationNon-HispanicNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyNutrition Examination SurveyPopulation-based screeningMultiple myelomaNHW counterpartsExamination SurveyMGUS prevalenceMonoclonal gammopathyIncidence rateNHWNatural history of MMMM incidenceNHBIncidence of monoclonal gammopathyCumulative riskHistory of MMMGUS to MMPopulation age distributionEpidemiologyAsymptomatic incidenceTreatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma
Fiala M, Ji M, Shih Y, Huber J, Wang M, Johnson K, Gasoyan H, Wang R, Colditz G, Wang S, Chang S. Treatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia 2024, 25: 109-115. PMID: 39209567, PMCID: PMC12179426, DOI: 10.1016/j.clml.2024.07.017.Peer-Reviewed Original ResearchStem cell transplantationCell transplantationMyeloma therapyMultiple myelomaContinuous enrollmentAssociated with early detectionMulti-State Medicaid DatabaseMultivariate logistic regressionMyeloma patientsSolid tumorsHigh medical needMyeloma treatmentHematological cancersMyelomaPatientsMedicaid databaseClaims-based datasetScreening testAcute medical eventsLogistic regressionEarly detectionDiscontinuous enrollmentMedical needContinuous Medicaid coverageCancer diagnosisFrom criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity.
Ji M, Wang M, Shih Y, Huber J, Fiala M, Wang R, Sanfilippo K, Thomas T, Wang S, Schoen M, Chang S. From criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity. Journal Of Clinical Oncology 2024, 42: 7556-7556. DOI: 10.1200/jco.2024.42.16_suppl.7556.Peer-Reviewed Original ResearchInternational Myeloma Working GroupMagnetic resonance imagingFree light chainsMGUS patientsMM casesActive MMDiagnostic criteriaMultiple myelomaPlasma cellsClonal bone marrow plasma cellsComputed tomographyOld criteriaPositron emission tomography-CTBone marrow plasma cellsSerum free light chainsSLiM-CRAB criteriaProgression to MMClonal plasma cellsMarrow plasma cellsMM patient outcomePlasma cell malignancyAggressive diagnostic strategyInternational Classification of Diseases (ICD)-9/10 codesCRAB symptomsPositive detection rateRacial differences in treatment and survival among older patients with multiple myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.Peer-Reviewed Original ResearchNon-Hispanic whitesNon-Hispanic white patientsMultiple myelomaRacial differencesHazard ratioReceipt of treatmentOlder patientsIncreasing racial disparitiesIntroduction of novel agentsCox proportional hazards modelsMultivariate Cox proportional hazards modelLower mortalityStudy investigated racial differencesAssess survival outcomesProportional hazards modelNon-HispanicProportion of patientsMedicare beneficiariesRacial disparitiesTreatment utilizationHazards modelSurvival outcomesNovel agentsMM survivalMM treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply